These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 28445188)

  • 1. TPMT, COMT and ACYP2 genetic variants in paediatric cancer patients with cisplatin-induced ototoxicity.
    Thiesen S; Yin P; Jorgensen AL; Zhang JE; Manzo V; McEvoy L; Barton C; Picton S; Bailey S; Brock P; Vyas H; Walker D; Makin G; Bandi S; Pizer B; Hawcutt DB; Pirmohamed M
    Pharmacogenet Genomics; 2017 Jun; 27(6):213-222. PubMed ID: 28445188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and genetic associations for carboplatin-related ototoxicity in children treated for retinoblastoma: A retrospective noncomparative single-institute experience.
    Soliman SE; D'Silva CN; Dimaras H; Dzneladze I; Chan H; Gallie BL
    Pediatr Blood Cancer; 2018 May; 65(5):e26931. PubMed ID: 29350448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy.
    Ross CJ; Katzov-Eckert H; Dubé MP; Brooks B; Rassekh SR; Barhdadi A; Feroz-Zada Y; Visscher H; Brown AM; Rieder MJ; Rogers PC; Phillips MS; Carleton BC; Hayden MR;
    Nat Genet; 2009 Dec; 41(12):1345-9. PubMed ID: 19898482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of genetic variants in TPMT and COMT associated with cisplatin induced hearing loss in patients with cancer: two new cohorts and a meta-analysis reveal significant heterogeneity between cohorts.
    Hagleitner MM; Coenen MJ; Patino-Garcia A; de Bont ES; Gonzalez-Neira A; Vos HI; van Leeuwen FN; Gelderblom H; Hoogerbrugge PM; Guchelaar HJ; Te Loo MW
    PLoS One; 2014; 9(12):e115869. PubMed ID: 25551397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The analysis of the association of the polymorphic variants of the TPMT, COMT, and ABCC3 genes with the development of hearing disorders induced by the cisplatin treatment].
    Mironovich OL; Bliznetz EA; Garbaruk ES; Belogurova MB; Subora NV; Varfolomeeva SR; Kachanov DY; Shamanskaya TV; Markova TG; Polyakov AV
    Vestn Otorinolaringol; 2018; 83(4):60-66. PubMed ID: 30113582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss.
    Xu H; Robinson GW; Huang J; Lim JY; Zhang H; Bass JK; Broniscer A; Chintagumpala M; Bartels U; Gururangan S; Hassall T; Fisher M; Cohn R; Yamashita T; Teitz T; Zuo J; Onar-Thomas A; Gajjar A; Stewart CF; Yang JJ
    Nat Genet; 2015 Mar; 47(3):263-6. PubMed ID: 25665007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Replication of a genetic variant in ACYP2 associated with cisplatin-induced hearing loss in patients with osteosarcoma.
    Vos HI; Guchelaar HJ; Gelderblom H; de Bont ES; Kremer LC; Naber AM; Hakobjan MH; van der Graaf WT; Coenen MJ; te Loo DM
    Pharmacogenet Genomics; 2016 May; 26(5):243-7. PubMed ID: 26928270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of inherited TPMT and COMT genetic variation in cisplatin-induced ototoxicity in children with cancer.
    Yang JJ; Lim JY; Huang J; Bass J; Wu J; Wang C; Fang J; Stewart E; Harstead EH; E S; Robinson GW; Evans WE; Pappo A; Zuo J; Relling MV; Onar-Thomas A; Gajjar A; Stewart CF
    Clin Pharmacol Ther; 2013 Aug; 94(2):252-9. PubMed ID: 23820299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Further Investigation of the Role of
    Drögemöller BI; Brooks B; Critchley C; Monzon JG; Wright GEB; Liu G; Renouf DJ; Kollmannsberger CK; Bedard PL; Hayden MR; Gelmon KA; Carleton BC; Ross CJD
    Clin Cancer Res; 2018 Apr; 24(8):1866-1871. PubMed ID: 29358504
    [No Abstract]   [Full Text] [Related]  

  • 10. Challenges in interpreting the evidence for genetic predictors of ototoxicity.
    Ratain MJ; Cox NJ; Henderson TO
    Clin Pharmacol Ther; 2013 Dec; 94(6):631-5. PubMed ID: 24241639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of Cisplatin Dose Intensity and TPMT Variation in the Development of Hearing Loss in Children.
    Siemens A; Brooks B; Rassekh SR; Meijer AJM; van den Heuvel-Eibrink MM; Xu W; Loucks CM; Ross CJD; Carleton BC;
    Ther Drug Monit; 2023 Jun; 45(3):345-353. PubMed ID: 36917731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic Review and Meta-Analysis of the Influence of Genetic Variation on Ototoxicity in Platinum-Based Chemotherapy.
    Hong DZ; Ong TCC; Timbadia DP; Tan HTA; Kwa ED; Chong WQ; Goh BC; Loh WS; Loh KS; Tan EC; Tay JK
    Otolaryngol Head Neck Surg; 2023 Jun; 168(6):1324-1337. PubMed ID: 36802061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Usefulness of current candidate genetic markers to identify childhood cancer patients at risk for platinum-induced ototoxicity: Results of the European PanCareLIFE cohort study.
    Langer T; Clemens E; Broer L; Maier L; Uitterlinden AG; de Vries ACH; van Grotel M; Pluijm SFM; Binder H; Mayer B; von dem Knesebeck A; Byrne J; van Dulmen-den Broeder E; Crocco M; Grabow D; Kaatsch P; Kaiser M; Spix C; Kenborg L; Winther JF; Rechnitzer C; Hasle H; Kepak T; van der Kooi AF; Kremer LC; Kruseova J; Bielack S; Sorg B; Hecker-Nolting S; Kuehni CE; Ansari M; Kompis M; van der Pal H; Parfitt R; Deuster D; Matulat P; Tillmanns A; Tissing WJE; Beck JD; Elsner S; Am Zehnhoff-Dinnesen A; van den Heuvel-Eibrink MM; Zolk O;
    Eur J Cancer; 2020 Oct; 138():212-224. PubMed ID: 32905960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of TPMT and COMT genetic variation in cisplatin-induced ototoxicity.
    Carleton BC; Ross CJ; Bhavsar AP; Amstutz U; Pussegoda K; Visscher H; Lee JW; Brooks B; Rassekh SR; Dubé MP; Hayden MR
    Clin Pharmacol Ther; 2014 Mar; 95(3):253. PubMed ID: 24193170
    [No Abstract]   [Full Text] [Related]  

  • 15. Replication of TPMT and ABCC3 genetic variants highly associated with cisplatin-induced hearing loss in children.
    Pussegoda K; Ross CJ; Visscher H; Yazdanpanah M; Brooks B; Rassekh SR; Zada YF; Dubé MP; Carleton BC; Hayden MR;
    Clin Pharmacol Ther; 2013 Aug; 94(2):243-51. PubMed ID: 23588304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic variation of cisplatin-induced ototoxicity in non-cranial-irradiated pediatric patients using a candidate gene approach: The International PanCareLIFE Study.
    Clemens E; Broer L; Langer T; Uitterlinden AG; de Vries ACH; van Grotel M; Pluijm SFM; Binder H; Byrne J; Broeder EVD; Crocco M; Grabow D; Kaatsch P; Kaiser M; Kenborg L; Winther JF; Rechnitzer C; Hasle H; Kepak T; van der Kooi AF; Kremer LC; Kruseova J; Kuehni CE; van der Pal H; Parfitt R; Deuster D; Matulat P; Spix C; Tillmanns A; Tissing WJE; Maier L; Am Zehnhoff-Dinnesen A; Zolk O; van den Heuvel-Eibrink MM;
    Pharmacogenomics J; 2020 Apr; 20(2):294-305. PubMed ID: 31666714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetics of cisplatin ototoxicity: confirming the unexplained?
    Boddy AV
    Clin Pharmacol Ther; 2013 Aug; 94(2):198-200. PubMed ID: 23872836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenomics of cisplatin-induced ototoxicity.
    Mukherjea D; Rybak LP
    Pharmacogenomics; 2011 Jul; 12(7):1039-50. PubMed ID: 21787192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The genetic vulnerability to cisplatin ototoxicity: a systematic review.
    Tserga E; Nandwani T; Edvall NK; Bulla J; Patel P; Canlon B; Cederroth CR; Baguley DM
    Sci Rep; 2019 Mar; 9(1):3455. PubMed ID: 30837596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic Variants as Predictive Markers for Ototoxicity and Nephrotoxicity in Patients with Locally Advanced Head and Neck Cancer Treated with Cisplatin-Containing Chemoradiotherapy (The PRONE Study).
    Driessen CM; Ham JC; Te Loo M; van Meerten E; van Lamoen M; Hakobjan MH; Takes RP; van der Graaf WT; Kaanders JH; Coenen MJH; van Herpen CM
    Cancers (Basel); 2019 Apr; 11(4):. PubMed ID: 30999660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.